HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial
Hepatic Arterial Infusion Chemotherapy Plus Toripalimab Versus Hepatic Arterial Infusion Chemotherapy Plus Sorafenib for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: a Non-comparative, Prospective, Randomized Trial
Sponsor: Sun Yat-sen University
A PHASE2 clinical study on Hepatocellular Carcinoma, this trial is ongoing. The trial is conducted by Sun Yat-sen University and has accumulated 7 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Oct 2025 — Present [monthly]
Unknown PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — Oct 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
-
Nov 2021 — Sep 2023 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jan 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Recruiting PHASE2
First recorded
Oct 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sun Yat-sen University
For direct contact, visit the study record on ClinicalTrials.gov .